263 related articles for article (PubMed ID: 23340040)
1. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.
Baird K; Steinberg SM; Grkovic L; Pulanic D; Cowen EW; Mitchell SA; Williams KM; Datiles MB; Bishop R; Bassim CW; Mays JW; Edwards D; Cole K; Avila DN; Taylor T; Urban A; Joe GO; Comis LE; Berger A; Stratton P; Zhang D; Shelhamer JH; Gea-Banacloche JC; Sportes C; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):632-9. PubMed ID: 23340040
[TBL] [Abstract][Full Text] [Related]
2. Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.
Kerep AZ; Broome J; Pirsl F; Curtis LM; Steinberg SM; Mitchell SA; Cowen EW; Pichard DC; Joe GO; Comis LE; Mays JW; Datiles MB; Stratton P; Zolton J; Berger A; Hendricks J; Kenyon M; Baruffaldi J; Titarenko I; Pulanic D; Baird K; Fowler DH; Gress RE; Pavletic SZ
Bone Marrow Transplant; 2019 Jan; 54(1):76-84. PubMed ID: 30089900
[TBL] [Abstract][Full Text] [Related]
3. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
4. NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.
Curtis LM; Grkovic L; Mitchell SA; Steinberg SM; Cowen EW; Datiles MB; Mays J; Bassim C; Joe G; Comis LE; Berger A; Avila D; Taylor T; Pulanic D; Cole K; Baruffaldi J; Fowler DH; Gress RE; Pavletic SZ
Bone Marrow Transplant; 2014 Dec; 49(12):1513-20. PubMed ID: 25153693
[TBL] [Abstract][Full Text] [Related]
5. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
Merkel EC; Mitchell SA; Lee SJ
Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
8. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.
Arai S; Jagasia M; Storer B; Chai X; Pidala J; Cutler C; Arora M; Weisdorf DJ; Flowers ME; Martin PJ; Palmer J; Jacobsohn D; Pavletic SZ; Vogelsang GB; Lee SJ
Blood; 2011 Oct; 118(15):4242-9. PubMed ID: 21791424
[TBL] [Abstract][Full Text] [Related]
9. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.
Palmer J; Williams K; Inamoto Y; Chai X; Martin PJ; Tomas LS; Cutler C; Weisdorf D; Kurland BF; Carpenter PA; Pidala J; Pavletic SZ; Wood W; Jacobsohn D; Arai S; Arora M; Jagasia M; Vogelsang GB; Lee SJ
Biol Blood Marrow Transplant; 2014 Mar; 20(3):337-44. PubMed ID: 24315845
[TBL] [Abstract][Full Text] [Related]
11. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.
Herzberg PY; Heussner P; Mumm FH; Horak M; Hilgendorf I; von Harsdorf S; Hemmati P; Rieger K; Greinix H; Freund M; Lee SJ; Holler E; Wolff D
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1707-17. PubMed ID: 20541028
[TBL] [Abstract][Full Text] [Related]
12. Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity.
Aki SZ; Inamoto Y; Carpenter PA; Storer BE; Sandmaier BM; Lee SJ; Martin PJ; Flowers ME
Bone Marrow Transplant; 2016 Oct; 51(10):1350-1353. PubMed ID: 27214071
[TBL] [Abstract][Full Text] [Related]
13. Validation of the National Institutes of Health (NIH) scale for oral chronic graft-versus-host disease (cGVHD).
Elad S; Zeevi I; Or R; Resnick IB; Dray L; Shapira MY
Biol Blood Marrow Transplant; 2010 Jan; 16(1):62-9. PubMed ID: 19733252
[TBL] [Abstract][Full Text] [Related]
14. Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classifications.
Del Fante C; Scudeller L; Viarengo G; Bernasconi P; Perotti C
Transfusion; 2012 Sep; 52(9):2007-15. PubMed ID: 22320219
[TBL] [Abstract][Full Text] [Related]
15. Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium.
Pidala J; Chai X; Martin P; Inamoto Y; Cutler C; Palmer J; Weisdorf D; Pavletic S; Arora M; Jagasia M; Jacobsohn D; Lee SJ
Biol Blood Marrow Transplant; 2013 Jun; 19(6):967-72. PubMed ID: 23542686
[TBL] [Abstract][Full Text] [Related]
16. Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.
Curtis LM; Pirsl F; Steinberg SM; Mitchell SA; Baird K; Cowen EW; Mays J; Buxbaum NP; Pichard DC; Im A; Avila D; Taylor T; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1980-1988. PubMed ID: 28797782
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
18. Evolving concepts in prognostic scoring of chronic GvHD.
Lazaryan A; Arora M
Bone Marrow Transplant; 2017 Oct; 52(10):1361-1366. PubMed ID: 28346419
[TBL] [Abstract][Full Text] [Related]
19. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality.
Pidala J; Kim J; Anasetti C; Nishihori T; Betts B; Field T; Perkins J
Haematologica; 2011 Nov; 96(11):1678-84. PubMed ID: 21791465
[TBL] [Abstract][Full Text] [Related]
20. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.
Kim DY; Lee JH; Lee JH; Kim SH; Lim SN; Kim SD; Choi Y; Lee YS; Kang YA; Kang SI; Seol M; Ryu SG; Lee KH
Bone Marrow Transplant; 2010 Jul; 45(7):1174-80. PubMed ID: 19915630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
